a year ago

Biofidelity Secures $24M to Advance Cancer Treatment Solutions

  • Biofidelity, a genomic technology company based in Cambridge, UK and Morrisville, NC, has raised $24 million in funding

  • The investment was led by Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures

  • The funds will be used to accelerate growth, including commercial and clinical expansion in the United States, establish a dedicated manufacturing facility in the United Kingdom, and drive pipeline expansion efforts across the company's technology platforms.

      • ProblemHealthcare

      "It takes weeks and costs a lot to determine which treatment is best for a patient with Non-Small Cell Lung Cancer (NSCLC), so patients may not get the best treatment and it's expensive for the healthcare system."

      Solution

      "ASPYRE®-Lung is a new test that quickly and cheaply identifies biomarkers for NSCLC, allowing doctors to personalize treatment for each patient, leading to better outcomes and lower costs."

      Covered on